The strong operational momentum (record revenue, margins, positive cash flow) is offset by a revenue miss and a new Israeli anti-dumping investigation that could materially impact the key Israel segment. Monitor the investigation's progress and the closure of the CanAdelaar acquisition. The stock may trade range-bound until regulatory clarity emerges.
Price Chart
Executive Summary
Cronos Group reported Q2 2026 results with record net revenue of $53.0M (+58% YoY) and record gross profit of $28.5M (+96% YoY), swinging to net income of $35.7M from a -$38.5M loss. However, revenue missed consensus estimates of $61.2M by 13.4%, and a new Israeli anti-dumping investigation on medical cannabis imports from Canada introduces regulatory overhang on the key Israel segment.
Key Financial Metrics
Key Facts
- Record net revenue $53.0M (+58% YoY, +51% constant-currency)
- Record gross profit $28.5M (+96% YoY), gross margin expanded 11pp to 54%
- Record Adjusted EBITDA $13.1M (+675% YoY)
- Net income $35.7M vs net loss -$38.5M in Q2 2025, helped by $20.2M foreign currency gains
- Revenue missed consensus $61.2M estimate by 13.4%
- EPS of $0.09 beat $0.01 consensus by 800% due to one-time FX gains
- Israeli anti-dumping investigation initiated Aug 5, 2026, creating regulatory risk for Israel segment (28% of revenue)
- Repurchased 12.3M shares in H1 2026; cash+investments of $827M
Financial Impact
Revenue miss of $8.2M vs consensus; regulatory risk from anti-dumping probe could affect ~$15M quarterly Israel revenue
Risk Factors
- Israeli anti-dumping investigation could lead to tariffs or import restrictions on Canadian cannabis, hitting 28% of revenue
- Revenue miss vs consensus suggests market expectations may have been too high for Q2
- EPS beat driven by non-operating FX gains, not core earnings power
- Pending CanAdelaar acquisition in Netherlands faces regulatory uncertainty
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3340162 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 8-K | $3.20 $3.21 | ▲ +0.31% | ▲ +1.42% | $3.34 (+4.31%) |
Oct 15, 2026 12d ago | Press Release | $3.20 $3.21 | ▲ +0.31% | ▲ +1.42% | $3.34 (+4.31%) |
Aug 6, 2026 11w ago | 8-K | $3.07 $3.10 | ▲ +0.98% | ▲ +0.37% | $3.34 (+8.73%) |
Aug 6, 2026 11w ago | Press Release | $3.07 $3.10 | ▲ +0.98% | ▲ +0.37% | $3.34 (+8.73%) |
Jul 16, 2026 14w ago | Press Release | $2.75 | awaiting T+1 | — | $3.34 (+21.38%) |
Jun 16, 2026 18w ago | Press Release | $2.67 $2.71 | ▲ +1.50% | ▲ +0.72% | $3.34 (+25.02%) |
May 11, 2026 24w ago | 8-K | $2.75 $2.77 | ▲ +0.73% | ▲ +0.86% | $3.34 (+21.38%) |
Apr 20, 2026 27w ago | Press Release | $2.76 | awaiting T+1 | — | $3.34 (+20.94%) |
Feb 26, 2026 34w ago | 8-K | $2.67 $2.67 | · 0.00% | ▲ +0.45% | $3.34 (+25.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers